Patents Examined by Joseph Murphy
  • Patent number: 7189530
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: March 13, 2007
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Margaret Ann Roy, Colin K. Watanabe, William I. Wood
  • Patent number: 7189533
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: March 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7189534
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: March 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7160993
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: January 9, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Maureen Beresini, Laura DeForge, Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Steven Sherwood, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Patent number: 7157248
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing a novel isoform of the ?2? subunit of a voltage gated calcium channel, herein named as ?2?-4. The isolated nucleic acid or polypeptide molecule of the invention can be used in diagnosing and treating a disease or disorder associated with a defective ?2?-4 subunit, such as seizure-related syndromes, anxiety, multiple sclerosis, and the like.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: January 2, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd
  • Patent number: 7153665
    Abstract: The invention relates to methods and compositions useful in screening for modulators of IgE synthesis, secretion and switch rearrangement.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: December 26, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: David A. Ferrick, Susan E. Swift, Randall Armstrong, Bryan Fox
  • Patent number: 7122345
    Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: October 17, 2006
    Assignee: CuraGen Corporation
    Inventor: Muralidhara Padigaru
  • Patent number: 7122630
    Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 17, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Helena Mancebo
  • Patent number: 7122332
    Abstract: The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: October 17, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Brian Wong, Chong Alan Fu, Helena Mancebo, Xiulan X. Z. Zhou
  • Patent number: 7109318
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 19, 2006
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Margaret Ann Roy, Colin K. Watanabe, William I. Wood
  • Patent number: 7101687
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7094577
    Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: August 22, 2006
    Assignee: Aventis Behring L.L.C.
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gérard Jung, Patrice Yeh
  • Patent number: 7084106
    Abstract: The present invention provides a novel treatment for senile dementia (Alzheimer's Type), comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the production or enlargement of amyloid plaques in the brain of the patient. The present invention further provides pharmaceutical compositions comprising anti-complement protein, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: August 1, 2006
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Girish J. Kotwal, James Daly, IV
  • Patent number: 7083932
    Abstract: The present invention is related to nucleic acid molecules, the peptides encoded by said nucleic acid moleucles and the inhibitors direacted against said nucleic acid molecules or said peptides. The present invention concerns also the pharmaceutical composition, the diagnostic and/or dosage device comprising said products and methods for identifying the inhibitors according to the invention.
    Type: Grant
    Filed: August 14, 1996
    Date of Patent: August 1, 2006
    Assignee: Euroscreen, s.a.
    Inventors: Marc Parmentier, Gilbert Vassart, Jean-Claude Meunier, Catherine Mollereau
  • Patent number: 7081354
    Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: July 25, 2006
    Assignee: Aventis Behring L.L.C.
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gérard Jung, Patrice Yeh
  • Patent number: 7081241
    Abstract: The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: July 25, 2006
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ann Marie Schmidt, David Stern
  • Patent number: 7074897
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: July 11, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7074910
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: July 11, 2006
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Steven Sherwood, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood
  • Patent number: 7071310
    Abstract: The present invention relates to an antibody capable of binding to human TLR2 and which (i) binds only to CD14+ cells in a normal human mononuclear cell population, and not to CD14? cells; (ii) does not inhibit LPS-induced activation of normal human mononuclear cells, and to the uses thereof, for example in the treatment of bacterial infections which are mediated via the TLR2 receptor, especially bacterial sepsis. In a particular embodiment of this aspects, a utility in the treatment of Listeria infections is proposed. The antibodies also have a utility as a general research tool, for example in screening for TLR2 expression, and in the study of TLR2 function. A further aspect of the invention provides use of an agent capable of inhibiting TLR2 activation in the preparation of a composition for the treatment of Listeria infections.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: July 4, 2006
    Assignee: Leiv Eiriksson Nyskaping AS
    Inventors: Terje Espevik, Anders Sundan
  • Patent number: RE39433
    Abstract: A therapeutic agent capable of of binding to the F?-G? loop of domain 4 of the common c Chain of the receptor for GM-CSF, IL-3, and IL-5. The amino acid Tyr421 which is located in the F?-G? loop is critical in the high affinity binding and stimulation of function of GM-CSF, IL-3 and IL-5 to the common c chain of the receptors. Other receptors for cytokines also show hydrophobic amino acids in analogous positions and it is probable that they too play a pivotal role in binding of respective cytokines to them and in modulating function. Agents capable of binding to the F?-G? loops are suggested and should be of therapeutic value.
    Type: Grant
    Filed: January 29, 1997
    Date of Patent: December 19, 2006
    Assignee: Medvet Science Pty, Ltd.
    Inventors: Angel Lopez, Christopher Bagley, Joanna Woodcock